Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Medicines Company | NASDAQ:MDCO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 84.90 | 84.00 | 84.94 | 0 | 00:00:00 |
From Nov 2019 to Nov 2024
By Chris Wack
The Medicines Co. (MDCO) shares rose 23%, to $84.00, after Novartis AG (NVS) said it was buying the company for $85 a share in an all-cash transaction
That price implies a fully diluted equity value of $9.7 billion, and represents a premium of 45% to The Medicines Co.'s closing share price of $58.65 on Nov. 18.
The company said completion of the transaction is expected in first quarter of 2020, and until that time, The Medicines Co. will continue to operate as a separate and independent company. The company expects to file regulatory submissions for inclisiran in the U.S. in the fourth quarter of 2019 and in Europe in the first quarter of 2020.
On Monday, Baird cut its price target for the company to $85 a share from $100, and Oppenheimer raised its price target to $85 to $68 a share.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
November 25, 2019 09:54 ET (14:54 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Medicines Chart |
1 Month Medicines Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
